Haematologica, Vol 92, Issue 12, 1585-1589 doi:10.3324/haematol.11506
Copyright © 2007 by Ferrata Storti Foundation

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (7) Citing Articles via Google Scholar Google Scholar Articles by Cazzola, M. Search for Related Content PubMed PubMed Citation Articles by Cazzola, M.

Editorials and Perspectives

Somatic mutations of JAK2 exon 12 as a molecular basis of erythrocytosis

Mario Cazzola

University of Pavia Medical School, Department of Hematology, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy. E-mail: mario.cazzola{at}unipv.it

The human erythron is a highly specialized tissue that is responsible for oxygen transport.¹ It includes the erythroid marrow, where red cells are produced, circulating red cells, the reticuloendothelial system, where red cells are phagocytosed at the end of their life span, and the erythropoietin-producing cells in the kidney. Within the erythroid marrow, differentiation and maturation of erythroid progenitors and precursors are controlled by several peptides. The most important one is erythropoietin, which is primarily made by a single organ, the kidney, outside the bone marrow and participates in a classic negative feedback control system (Figure 1). In the kidney, erythropoietin production is restricted to specific subsets of cells, i.e., interstitial fibroblast-like cells, and hypoxia is the fundamental physiological stimulus that induces expression of the erythropoietin gene (EPO) in these cells.²

View larger version (19K): [in this window] [in a new window] [Download PPT slide]

Figure 1. Feedback regulation of red cell production.

Hypoxia inducible factor-1 (HIF-1) is the principal factor responsible for transcriptional activation of EPO.^3,4 HIF-1 is a heterodimeric transcription factor composed of HIF-1 and HIF-1β subunits, and functions as a master regulator of oxygen homeostasis activating hundreds of genes.^2,4 As illustrated in Figure 2, at normal oxygen tension, HIF-1 rapidly undergoes hydroxylation of proline residues by prolyl hydroxylase domain protein 2 (PHD2).⁵ The proline hydroxylated HIF-1 interacts with the von Hippel–Lindau protein (VHL), and this binding leads to ubiquitination and proteasomal degradation. At low oxygen tension, by contrast, HIF-1 is stable and forms a heterodimer with HIF-1β, generating the HIF-1 molecule. The heterodimer translocates into the nucleus, binds to response elements in hypoxia inducible genes, and activates their transcription. Thus, hypoxia rapidly increases renal production of erythropoietin through activation of HIF-1-mediated transcription of the EPO gene in interstitial erythropoietin-producing cells.

View larger version (21K): [in this window] [in a new window] [Download PPT slide]

Figure 2. Schematic representation of the HIF-1 oxygen-sensing pathway.

Erythropoietin exerts its effects by binding to a surface receptor (EPO-R) present on erythroid progenitors and precursors.⁶ While only a few receptors are found on early burst-forming units-erythroid (BFU-E), their number increases with differentiation and a peak of more than 1,000 receptors/cell is reached at the colony-forming unit-erythroid (CFU-E) and proerythroblast stages.⁷ EPO-R transduces the erythropoietin signal by activating members of the Janus kinase (JAK) family of proteins, which phosphorylate cytoplasmic targets, including the signal transducers and activators of transcription (STAT). JAK2 plays an essential role in hematopoiesis by mediating signals from several hematopoietic growth factors, including erythropoietin, thrombopoietin and granulocyte colony-stimulating factor (G-CSF). Erythropoietin mainly acts as a survival factor for erythroid cells with high receptor number, i.e. CFU-E and proerythroblasts.

The term erythrocytosis defines any condition characterized by increased values of hemoglobin, hematocrit and red blood cells. Absolute erythrocytosis is characterized by the presence of an increased red cell mass, while relative erythrocytosis is secondary to plasma volume depletion. According to its Greek etymology, polycythemia means many cells, and therefore this term should be used to define conditions characterized not only by erythrocytosis, but also by leukocytosis and/or thrombocytosis.

The measurement routinely employed for identifying erythrocytosis is hemoglobin concentration, whose upper normal limit varies according to several factors, including age, sex, ethnic group, and altitude at which the subject lives. Arbitrary upper limits may be 17 g/dL for the adult male and 16 g/dL for the adult female at sea level.¹ The fact that a hemoglobin level is above these limits does not necessarily mean that it is abnormal and the subject has erythrocytosis. Since there are overlaps between normal individuals and patients with respect to hemoglobin level,¹ the interpretation of an individual value that lies outside the reference range should rely upon a probability calculation. In general, the higher the hemoglobin level, the more likely it is that the value represents erythrocytosis. More stringent limits would, therefore, be those adopted by the WHO for the diagnosis of polycythemia vera, i.e., 18.5 g/dL in men, 16.5 g/dL in women, or the 99^th percentile of a method-specific reference range for age, sex, and altitude of residence.⁸

A classification of absolute erythrocytosis was previously reported in this journal.⁹ Table 1 reports a classification of absolute erythrocytosis due to germline or somatic mutations of genes involved in the regulation of erythropoiesis. While germline mutations are responsible for hereditary conditions,^10–12 the somatic ones are typically found in acquired myeloproliferative disorders.

View this table: [in this window] [in a new window] [Download PPT slide]

Table 1. Classification of erythrocytosis due to germline or somatic mutations of genes involved in the regulation of erythropoiesis.

By using sensitive assays, the gain-of-function JAK2 (V617F) mutation – which involves exon 14 of the gene – can be detected in the vast majority of patients with sporadic polycythemia vera,^13–15 but only in about half of those with familial polycythemia vera.¹⁶ This unique mutation is rarely found in patients with the so-called idiopathic erythrocytosis,¹⁷ a poorly defined condition characterized by erythrocytosis of undefined origin. According to Wikipedia, idiopathic is an adjective used primarily in medicine meaning arising spontaneously or from an obscure or unknown cause. This term derives from the Greek idios – which means one’s own – and pathos – which means disease in this context. Thus, idiopathic basically means a disease of its own kind. In other words, this adjective defines physicians’ lack of knowledge.

Somatic mutations of JAK2 exon 12 have been recently found in patients with either polycythemia vera or idiopathic erythrocytosis who do not carry the unique exon 14 mutation (Table 2).^18–21 Compared with patients with JAK2 (V617F)-positive polycythemia vera, patients with polycythemia vera carrying exon 12 mutations have a clinical phenotype mainly characterized by isolated erythrocytosis. In this issue of the journal, Percy and co-workers²² and Martinez-Aviles and co-workers²³ report interesting additional observations on JAK2 exon 12 mutations in patients with idiopathic erythrocytosis. In the British study,²² these mutations were detected in a proportion of patients with low serum erythropoietin levels, all of whom had erythropoietin-independent erythroid progenitors. Two of the three Spanish patients with idiopathic erythrocytosis carrying exon 12 mutations also had very low serum erythropoietin levels.²³ Thus, these patients have a myeloproliferative disorder mainly characterized by autonomous overproduction of red cells associated with secondary suppression of erythropoietin synthesis. This pattern has been recently observed by us²⁴ also in patients with polycythemia vera carrying exon 12 mutations.

View this table: [in this window] [in a new window] [Download PPT slide]

Table 2. JAK2 exon 12 mutations reported so far.18–24

There is considerable discrepancy in the frequency of exon 12 mutations in patients with JAK2 (V617F)-negative polycythemia vera between three studies^18,19,21 in which virtually all patients were found to be positive, and others^20,23 in which less than half of the patients were so. One source of the discrepancy is likely the detection method employed. In any given tissue, a somatic mutation is found in a variable proportion of alleles. Exon 12 mutations are likely associated with small clones initially, and therefore present in small percentages of granulocyte alleles. For their detection, allele-specific PCR is definitely superior to direct sequencing, whose sensitivity is about 10% of mutant alleles. A second crucial issue is the source of DNA for mutation detection. The available evidence suggests that exon 12 mutations may preferentially lead to expansion of erythroid cells within the bone marrow. Therefore, endogenous erythroid colonies appear to be more suitable sources of DNA than granulocytes for detection of these mutations. These considerations clearly indicate that there is a need for highly sensitive, reliable and hopefully relatively simple methods for identifying JAK2 exon 12 mutations in patients with erythrocytosis.

So far, ten mutations of JAK2 exon 12 have been reported (Table 2), the most frequent ones being deletions that result in the loss of a 6 bp fragment. They do not disrupt the gene reading frame, but rather alter the final amino acid composition by removing two residues: N542-E543 and E543-D544del are the most frequent of these deletions. Analysis of the sequence across deletion breakpoints shows the presence of two short direct repeats (AGA) in the region involved in these rearrangements (Figure 3). This might facilitate the generation of single-stranded looped intermediates that might be either excluded by replication or cleaved through an enzymatic excision-repair mechanism, resulting in the loss of 6 bp fragments.

View larger version (31K): [in this window] [in a new window] [Download PPT slide]

Figure 3. Hypothetical mechanism of slippage mispairing involving the AGA repeats in exon 12 (shown in red) and leading to 6 bp deletions (see text for details concerning the mechanisms that can lead from slippage mispairing to the loss of 6 bp fragments in a hemopoietic stem cell). Numbers from 1 to 6 indicate possible deletion breakpoints, which may lead to R541–E543delinsK (1622–1627del6), N542–E543del (1623–1628del6 or 1624–1629del6), and E543–D544del (1625–1630del6 or 1626–1631del6 or 1627–1632del6). (Courtesy of Daniela Pietra, Angela Brisci and Laura Cremonesi)

The occurrence of the same JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis suggests that these conditions are simply different stages of the same erythrocytosic myeloproliferative disease (Figure 4). Patients with small mutant clones and marginally elevated hemoglobin levels would be categorized as having idiopathic erythrocytosis, while those with larger clones and hemoglobin levels above the WHO classification limits⁸ would meet the WHO diagnostic criteria for polycythemia vera. A few observations suggest that some of these latter patients may also have thrombocytosis and/or leukocytosis. Whether this reflects clone size, genetic background, or co-operating mutations remains to be established.

View larger version (33K): [in this window] [in a new window] [Download PPT slide]

Figure 4. Schematic representation of the clinical course of the human myeloproliferative disorder associated with JAK2 exon 12 mutations and characterized by isolated erythrocytosis, at least initially. The occurrence of a JAK2 exon 12 mutation in a hematopoietic stem cell gives rise to a clone. The increased red cell production in turn leads to erythrocytosis. This condition may be relatively stable for years or may progress. According to hemoglobin level and other WHO criteria, this disorder may be diagnosed as idiopathic erythrocytosis or polycythemia vera. Progression to full-blown polycythemia vera – characterized by thrombocytosis and/or leukocytosis – may occur during the clinical course, and extramedullary disease may eventually develop.

There is no doubt that the identification of JAK2 (V617F) has opened avenues of research, along which neglected Cinderellas – Philadelphia-negative myeloproliferative disorders – have achieved triumphant rewards. It is to be hoped that the adjective idiopathic will become obsolete in the forthcoming molecular hematology era. Some patients currently diagnosed with a idiopathic erythrocytosis will be diagnosed with hereditary disease or myeloproliferative disorder. Others will be simply defined as normal individuals with constitutively high hemoglobin levels, perhaps related to gene polymorphisms.

References

1. Hillman RS, Finch CA. Red Cell Manual. 5. Philadelphia: F.A. Davis. 1985.
2. Ebert BL, Bunn HF. Regulation of the erythropoietin gene. Blood 1999;94:1864-77.[Free Full Text]
3. Cockman ME, Pugh CW. Oxygen sensing. Haematologica 2005;90:8-12.[Free Full Text]
4. Semenza GL. Life with oxygen. Science 2007;318:62-4.[Abstract/Free Full Text]
5. Semenza GL. Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE 2007;2007:cm8.[Abstract/Free Full Text]
6. D’Andrea AD, Zon LI. Erythropoietin receptor. Subunit structure and activation. J Clin Invest 1990;86:681-7.[Web of Science][Medline]
7. Broudy VC, Lin N, Brice M, Nakamoto B, Papayannopoulou T. Erythropoietin receptor characteristics on primary human erythroid cells. Blood 1991;77:2583-90.[Abstract/Free Full Text]
8. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092-7.[Abstract/Free Full Text]
9. Gordeuk VR, Stockton DW, Prchal JT. Congenital polycythemias/erythrocytoses. Haematologica 2005;90:109-16.[Abstract/Free Full Text]
10. Bento MC, Chang KT, Guan Y, Liu E, Caldas G, Gatti RA, et al. Congenital polycythemia with homozygous and heterozygous mutations of von Hippel-Lindau gene: five new Caucasian patients. Haematologica 2005;90:128-9.[Abstract/Free Full Text]
11. Cario H, Schwarz K, Jorch N, Kyank U, Petrides PE, Schneider DT, et al. Mutations in the von Hippel-Lindau (VHL) tumor suppressor gene and VHL-haplotype analysis in patients with presumable congenital erythrocytosis. Haematologica 2005;90:19-24.[Abstract/Free Full Text]
12. Randi ML, Murgia A, Putti MC, Martella M, Casarin A, Opocher G, et al. Low frequency of VHL gene mutations in young individuals with polycythemia and high serum erythropoietin. Haematologica 2005;90:689-91.[Abstract/Free Full Text]
13. Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E, Pascutto C, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006;107:3676-82.[Abstract/Free Full Text]
14. Cazzola M, Passamonti F. Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders. Haematologica 2006;91:159.[Free Full Text]
15. Cazzola M, Skoda R. Gain of function, loss of control – a molecular basis for chronic myeloproliferative disorders. Haematologica 2005;90:871-4.[Free Full Text]
16. Rumi E, Passamonti F, Della Porta MG, Elena C, Arcaini L, Vanelli L, et al. Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. J Clin Oncol 2007;in press.
17. Percy MJ, Jones FG, Green AR, Reilly JT, McMullin MF. The incidence of the JAK2 V617F mutation in patients with idiopathic erythrocytosis. Haematologica 2006;91:413-4.[Abstract/Free Full Text]
18. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356:459-68.[Abstract/Free Full Text]
19. Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007;21:1960-3.[CrossRef][Web of Science][Medline]
20. Williams DM, Kim AH, Rogers O, Spivak JL, Moliterno AR. Phenotypic variations and new mutations in JAK2 V617Fnegative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. Exp Hematol 2007;35:1641-6.[Medline]
21. Butcher CM, Hahn U, To LB, Gecz J, Wilkins EJ, Scott HS, et al. Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients. Leukemia 2007;[Epub ahead of print].
22. Percy MJ, Scott LM, Erber WN, Harrison CN, Jones FCG, Green AR, et al. JAK2 exon 12 mutations occurr frequently in idiopathic erythrocytosis patients with low serum erythropoietin levels. Haematologica 2007;92:1607-14.[Abstract/Free Full Text]
23. Martínez-Aviles L, Besses C, Alvarez-Larran A, Cervantes F, Hernandez-Boluda JC, Bellosillo B. JAK2 exon 12 mutations in patients with polycythemia vera or idiopathic erythrocytosis. Haematologica 2007;92:1717-18.[Abstract/Free Full Text]
24. Pietra D, Li S, Brisci A, Passamonti F, Rumi E, Theocharides A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood, Nov 6 2007;[Epub ahead of print].

This article has been cited by other articles:

				L. Zhao, H. Dong, C. C. Zhang, L. Kinch, M. Osawa, M. Iacovino, N. V. Grishin, M. Kyba, and L. J.-s. Huang A JAK2 Interdomain Linker Relays Epo Receptor Engagement Signals to Kinase Activation J. Biol. Chem., September 25, 2009; 284(39): 26988 - 26998. [Abstract] [Full Text] [PDF]

				F. Girodon, G. Bonicelli, C. Schaeffer, M. Mounier, S. Carillo, I. Lafon, P. M. Carli, I. Janoray, E. Ferrant, and M. Maynadie Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study Haematologica, June 1, 2009; 94(6): 865 - 869. [Abstract] [Full Text] [PDF]

				M. Al-Sheikh, E. Mazurier, B. Gardie, N. Casadevall, F. Galacteros, M. Goossens, H. Wajcman, C. Prehu, and V. Ugo A study of 36 unrelated cases with pure erythrocytosis revealed three new mutations in the erythropoietin receptor gene Haematologica, July 1, 2008; 93(7): 1072 - 1075. [Abstract] [Full Text] [PDF]

				M. Cazzola Molecular basis of thrombocytosis Haematologica, May 1, 2008; 93(5): 646 - 648. [Full Text] [PDF]

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (7) Citing Articles via Google Scholar Google Scholar Articles by Cazzola, M. Search for Related Content PubMed PubMed Citation Articles by Cazzola, M.